Immuno-Oncology | Specialty

FDA Grants Nivolumab Breakthrough Designation in Renal Cell Carcinoma

September 16th 2015

Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

Dr. Carolyn Britten on Next Steps in Immunotherapy

September 15th 2015

Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.

Nivolumab/Ipilimumab Combination Active in Advanced NSCLC

September 8th 2015

A chemotherapy-free regimen of nivolumab and ipilimumab demonstrated activity as a first-line therapy for patients with advanced non–small cell lung cancer.

Nivolumab Survival Benefit Sustained in Squamous NSCLC

September 8th 2015

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

Atezolizumab Plus Chemo Leads to High Response Rate in NSCLC

September 7th 2015

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

Breast Cancer Pioneer Examines Novel Therapies for Metastatic Breast Cancer

September 3rd 2015

Dennis Slamon, MD, PhD, discusses the inhibition of CDK 4/6 and PD-1, which represent two of the most exciting developments in the field of metastatic breast cancer.

FDA Grants Nivolumab Priority Review in Nonsquamous NSCLC

September 2nd 2015

Nivolumab (Opdivo) has received an FDA priority review designation for patients with previously treated nonsquamous non–small cell lung cancer.

Dr. Zafar on the Potential of Immunotherapy in Colorectal Cancer

August 31st 2015

S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).

Combination Therapies Continue to Advance in Melanoma

August 31st 2015

Anna Pavlick, DO, discusses immunotherapy and targeted combination regimens in advanced melanoma.

Cancer Immunotherapy Meets Precision Medicine in Biomarker Study

August 29th 2015

Mismatch repair deficiency may serve as an immuno-oncology biomarker and may illustrate the clinical utility of analyzing the number of mutations per tumor.

FDA Grants Intravesical Immunotherapy Priority Review for Bladder Cancer

August 28th 2015

The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.

Checkpoint Inhibitors Show Promise in Triple-Negative Breast Cancer

August 28th 2015

Immune checkpoint inhibitors can be of significant value in combatting recurrent and metastatic triple negative breast cancer, Rita Nanda, MD, told physicians at the recent 14th Annual International Congress on the Future of Breast Cancer.

Frontline Pembrolizumab Receives FDA Priority Review in Melanoma

August 18th 2015

The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma.

Lead Researcher Discusses Anti-PD-L1 Agent Avelumab in Ovarian Cancer

August 18th 2015

Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.

Atezolizumab Again Achieves Phase II Success in PD-L1-Positive Lung Cancer

August 17th 2015

Atezolizumab met the primary endpoint of objective response in PD-L1–positive patients with advanced non–small cell lung cancer in the phase II BIRCH trial.

Immunotherapy May Hold the Key to Attacking HPV-Associated Cancers

August 14th 2015

An improved understanding of the natural history of HPV, its interaction with the host immune system, and the distinct molecular alterations underlying HPV-positive cancers, are fueling development of new drugs, particularly immunotherapies geared toward generating an HPV-specific immune response.

FDA Delays Decision on Frontline Nivolumab in Melanoma

August 12th 2015

The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.

Novel Immunotherapeutic Agent Shows Benefit in Ovarian Cancer

August 10th 2015

Premal H. Thaker, MD, discusses EGEN-001 in combination with pegylated liposomal doxorubicin and the potential of immunotherapy agents in ovarian and other similar cancers.

Biomarker Chase Continues With Checkpoint Agents in Lung Cancer

August 10th 2015

Achieving true precision medicine with PD-1/PD-L1 agents in NSCLC will only come from biomarker-driven frontline regimens delivered to the right patients.

Role of Anti-PD-1/PD-L1 Immunotherapy in Cancer

August 6th 2015

Immunotherapy for the treatment of cancer has evolved alongside our improved understanding of the immune system.

NEXT PAGE
PREVIOUS PAGE